{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:31:19Z","timestamp":1772569879938,"version":"3.50.1"},"reference-count":28,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>The short-term benefits of bisphosphonates (BPs) are evident in the treatment of children with osteogenesis imperfecta (OI), but some concerns related to long-term effects remain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>To elucidate the effect of BPs on characteristics of femoral fractures in children with OI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and Setting:<\/jats:title>\n                  <jats:p>Retrospective cohort study at a university hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Main Outcome Measure:<\/jats:title>\n                  <jats:p>The study included 93 patients with OI. We recorded fracture histories and analyzed all femoral fractures for location and fracture type using radiographs obtained at fracture diagnosis. Effects of BPs were evaluated by comparing fracture characteristics in three groups: patients (1) naive to BPs, (2) receiving ongoing BP treatment, and (3) whose treatment was discontinued.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>In total, 127 femoral fractures occurred in 24 patients. Of the fractures, 63 (50%) occurred in patients naive to BPs, 44 (35%) during BP treatment, and 20 (16%) after treatment discontinuation. Mid or distal shaft fractures were most common (41%), followed by subtrochanteric (33%) and distal (20%) fractures. Almost all fractures were transverse (65%) or oblique (28%). The pattern of femoral fractures was similar in all three BP treatment groups (P = 0.78 for location; P = 0.35 for fracture type) and was not related to cumulative BP dose. Instead, OI type correlated with fracture characteristics, and distal location and transverse configuration were more common in the more severe types III and IV compared with type I OI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>Characteristics of femoral fractures in children with OI are affected by OI type but not by BP exposure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2016-3745","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T21:28:11Z","timestamp":1491514091000},"page":"1333-1339","source":"Crossref","is-referenced-by-count":24,"title":["Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta"],"prefix":"10.1210","volume":"102","author":[{"given":"Ilkka","family":"Vuorimies","sequence":"first","affiliation":[{"name":"Children's Hospital and"},{"name":"Folkh\u00e4lsan Institute of Genetics, 00029 Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervi K.","family":"M\u00e4yr\u00e4np\u00e4\u00e4","sequence":"additional","affiliation":[{"name":"Department of Pediatric Radiology, Helsinki Medical Imaging Center, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Valta","sequence":"additional","affiliation":[{"name":"Children's Hospital and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heikki","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"Bone and Cartilage Research Unit, University of Eastern Finland and Kuopio University Hospital, 70029 Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanna","family":"Toiviainen-Salo","sequence":"additional","affiliation":[{"name":"Department of Pediatric Radiology, Helsinki Medical Imaging Center, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Outi","family":"M\u00e4kitie","sequence":"additional","affiliation":[{"name":"Children's Hospital and"},{"name":"Folkh\u00e4lsan Institute of Genetics, 00029 Helsinki, Finland"},{"name":"Center for Molecular Medicine, Karolinska Institutet, and Clinical Genetics, Karolinska University Hospital, 17176 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"issue":"9418","key":"2020071618590205200_B1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"2020071618590205200_B2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2020071618590205200_B3","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1210\/jc.2013-1505","article-title":"New genes in bone development: what\u2019s new in osteogenesis imperfecta","volume":"98","author":"Marini","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071618590205200_B4","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","volume":"164A","author":"Van Dijk","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"1","key":"2020071618590205200_B5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","article-title":"Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta","volume":"87","author":"Astr\u00f6m","year":"1998","journal-title":"Acta Paediatr"},{"issue":"9902","key":"2020071618590205200_B6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"issue":"14","key":"2020071618590205200_B7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"2020071618590205200_B8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000323368","article-title":"Zoledronic acid treatment in children with osteogenesis imperfecta","volume":"75","author":"Vuorimies","year":"2011","journal-title":"Horm Res Paediatr"},{"issue":"8","key":"2020071618590205200_B9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","article-title":"Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis","volume":"28","author":"Gedmintas","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2020071618590205200_B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2020071618590205200_B11","first-page":"278","article-title":"An atypical fracture in male patient with osteogenesis imperfecta","volume":"12","author":"Etxebarria-Foronda","year":"2015","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"10","key":"2020071618590205200_B12","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.4158\/EP14141.CR","article-title":"Atypical femoral fracture in an osteogenesis imperfecta patient successfully treated with teriparatide","volume":"20","author":"Holm","year":"2014","journal-title":"Endocr Pract"},{"issue":"3","key":"2020071618590205200_B13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1210\/jc.2012-4195","article-title":"The paradox of prevention--bilateral atypical subtrochanteric fractures due to bisphosphonates in osteogenesis imperfecta","volume":"98","author":"Manolopoulos","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071618590205200_B14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/17453674.2012.729183","article-title":"Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta--a case report","volume":"83","author":"Meier","year":"2012","journal-title":"Acta Orthop"},{"issue":"7","key":"2020071618590205200_B15","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jbmr.2805","article-title":"Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating?","volume":"31","author":"Vasanwala","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2020071618590205200_B16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11832-011-0380-0","article-title":"Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates","volume":"6","author":"Nicolaou","year":"2012","journal-title":"J Child Orthop"},{"issue":"5","key":"2020071618590205200_B17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/adc.2003.036590","article-title":"Bisphosphonate treatment of bone disease","volume":"90","author":"Shaw","year":"2005","journal-title":"Arch Dis Child"},{"issue":"2","key":"2020071618590205200_B18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/01241398-199103000-00008","article-title":"Fractures in early childhood: osteogenesis imperfecta or child abuse?","volume":"11","author":"Dent","year":"1991","journal-title":"J Pediatr Orthop"},{"issue":"4","key":"2020071618590205200_B19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/01241398-199010040-00014","article-title":"Pathologic fractures in severely handicapped children and young adults","volume":"10","author":"Lee","year":"1990","journal-title":"J Pediatr Orthop"},{"issue":"3","key":"2020071618590205200_B20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s002239900600","article-title":"The mineralization density of iliac crest bone from children with osteogenesis imperfecta","volume":"64","author":"Boyde","year":"1999","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2020071618590205200_B21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bone.2006.02.071","article-title":"Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta","volume":"39","author":"Weber","year":"2006","journal-title":"Bone"},{"issue":"9","key":"2020071618590205200_B22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"issue":"2","key":"2020071618590205200_B23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-001-1055-5","article-title":"The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta","volume":"72","author":"Shapiro","year":"2003","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2020071618590205200_B24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00774-007-0782-8","article-title":"Alendronate treatment promotes bone formation with a less anisotropic microstructure during intramembranous ossification in rats","volume":"26","author":"Kashii","year":"2008","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"2020071618590205200_B25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2020071618590205200_B26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bone.2009.11.019","article-title":"Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats","volume":"46","author":"Shahnazari","year":"2010","journal-title":"Bone"},{"issue":"2","key":"2020071618590205200_B27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2005-2036","article-title":"Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy","volume":"91","author":"Rauch","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071618590205200_B28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/4\/1333\/11205841\/jc.2016-3745.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/4\/1333\/11205841\/jc.2016-3745.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T04:13:39Z","timestamp":1594959219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/102\/4\/1333\/2913385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,17]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2016-3745","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,4,1]]},"published":{"date-parts":[[2017,1,17]]}}}